Prospects for extracorporeal liver support

Gut

Volumn 53, Issue 6, 2004, Pages 890-898

  Jalan, R ^a   Sen, S ^a   Williams, R ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DISEASE; BRAIN EDEMA; EXTRACORPOREAL CIRCULATION; HEMODIALYSIS; HUMAN; HYPOTENSION; INFECTION SENSITIVITY; KIDNEY FAILURE; LIVER FAILURE; LIVER SUPPORT; PRIORITY JOURNAL; REVIEW;

BIOARTIFICIAL ORGANS; CLINICAL TRIALS; EQUIPMENT DESIGN; EXTRACORPOREAL CIRCULATION; HUMANS; LIVER FAILURE; LIVER, ARTIFICIAL;

EID: 2442670129     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.024919     Document Type: Review

References (63)

1. Stockmann HB, JN IJ. Prospects for the temporary treatment of acute liver failure. Eur J Gastroenterol Hepatol 2002;14:195-203.
2. OPTN/SRTR data. 1 August 2002. www.optn.org.
3. Allen JW, Hassanein T, Bhatia SN. Advances in bioartificial liver devices. Hepatology 2001;34:447-55.
4. Strain AJ, Neuberger JM. A bioartificial liver - state of the art. Science 2002;295:1005-9.
5. Sussman NL, Chong MG, Koussayer T, et al. Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology 1992;16:60-5.
6. Rozga J, Williams F, Ro MS, et al. Development of a bioartificial liver: properties and function of a hollow-fiber module inoculated with liver cells. Hepatology 1993;17:258-65.
7. Flendrig LM, la Soe JW, Jorning GG, et al. In vitro evaluation of a novel bioreactor based on an integral oxygenator and a spirally wound nonwoven polyester matrix for hepatocyte culture as small aggregates. J Hepatol 1997;26:1379-92.
8. Gerlach JC, Schnoy N, Encke J, et al. Improved hepatocyte in vitro maintenance in a culture model with woven multicompartment capillary systems: electron microscopy studies. Hepatology 1995;22:546-52.
9. O'Grady JG, Gimson AE, O'Brien CJ, et al. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988;94:1186-92.
10. McGuire BM, Sielaff TD, Nyberg SL, et al. Review of support systems used in the management of fulminant hepatic failure. Dig Dis 1995;13:379-88.
11. Ash SR, Blake DE, Carr DJ, et al. Clinical effects of a sorbent suspension dialysis system in treatment of hepatic coma (the BioLogic-DT). Int J Artif Organs 1992;15:151-61.
12. Hughes RD, Pucknell A, Routley D, et al. Evaluation of the BioLogic-DT sorbent-suspension dialyser in patients with fulminant hepatic failure. Int J Artif Organs 1994;17:657-62.
13. Mitzner S, Stange J, Freytag J, et al. Role of transport proteins in bioartificial liver assist systems. Int J Artif Organs 1996;19:49-52.
14. Stange J, Mitzner S. A carrier-mediated transport of toxins in a hybrid membrane. Safety barrier between a patients blood and a bioartificial liver. Int J Artif Organs 1996;19:677-91.
15. Stange J, Mitzner S, Ramlow W, et al. A new procedure for the removal of protein bound drugs and toxins. Asaio J 1993;39:M621-5.
16. Mitzner SR, Stange J, Klammt S, et al. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol 2001;12(suppl 17):S75-82.
17. Sen S, Jalan R, Williams R. Extracorporeal albumin dialysis in acute-on-chronic liver failure: will it stand the test of time? Hepatology 2002;36:1014-16.
18. Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver 2002;22(Suppl 2):5-13.
19. Hughes RD, Cochrane AM, Thomson AD, et al. The cytotoxicity of plasma from patients with acute hepatic failure to isolated rabbit hepatocytes. Br J Exp Pathol 1976;57:348-53.
20. Nagasue N, Yukaya H, Ogawa Y, et al. Human liver regeneration after major hepatic resection. A study of normal liver and livers with chronic hepatitis and cirrhosis. Ann Surg 1987;206:30-9.
21. Arkadopoulos N, Lilja H, Suh KS, et al. Intrasplenic transplantation of allogeneic hepatocytes prolongs survival in anhepatic rats. Hepatology 1998;28:1365-70.
22. Riordan SM, Williams R. Acute liver failure: Targeted artificial and hepatocyte-based support of liver regeneration and reversal of multiorgan failure. J Hepatol 2000;32(suppl 1):63-76.
23. Wu L, Sun J, Wang L, et al. Cryopreservation of primary porcine hepatocytes for use in bioartificial liver support systems. Transplant Proc 2000;32:2271-2.
24. Yagi T, Hardin JA, Valenzuela YM, et al. Caspase inhibition reduces apoptotic death of cryopreserved porcine hepatocytes. Hepatology 2001;33:1432-40.
25. Baquerizo A, Mhoyan A, Shirwan H, et al. Xenoantibody response of patients with severe acute liver failure exposed to porcine antigens following treatment with a bioartificial liver. Transplant Proc 1997;29:964-5.
26. Nyberg SL, Hibbs JR, Hardin JA, et al. Influence of human fulminant hepatic failure sera on endogenous retroviral expression in pig hepatocytes. Liver Transpl 2000;6:76-84.
27. Patience C, Takeuchi Y, Weiss RA. Infection of human cells by an endogenous retrovirus of pigs. Nat Med 1997;3:282-6.
28. Martin U, Kiessig V, Blusch JH, et al. Expression of pig endogenous retrovirus by primary porcine endothelial cells and infection of human cells. Lancet 1998;352:692-4.
29. Wilson CA, Wong S, Muller J, et al. Type C retrovirus released from porcine primary peripheral blood mononuclear cells infects human cells. J Virol 1998;72:3082-7.
30. Nyberg SL, Hibbs JR, Hardin JA, et al. Transfer of porcine endogenous retrovirus across hollow fiber membranes: significance to a bioartificial liver. Transplantation 1999;67:1251-5.
31. Martin U, Winkler ME, Id M, et al. Productive infection of primary human endothelial cells by pig endogenous retrovirus (PERV). Xenotransplantation 2000;7:138-42.
32. Heneine W, Tibell A, Switzer WM, et al. No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts. Lancet 1998;352:695-9.
33. Paradis K, Langford G, Long Z, et al. Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. The XEN 111 Study Group. Science 1999;285:1236-41.
34. Patience C, Patton GS, Takeuchi. Y, et al. No evidence of pig DNA or retroviral infection in patients with short-term extracorporeal connection to pig kidneys. Lancet 1998;352:699-701.
35. Kono Y, Yang S, Letarte M, et al. Establishment of a human hepatocyte line derived from primary culture in a collagen gel sandwich culture system. Exp Cell Res 1995;221:478-85.
36. McCloskey P, Edwards RJ, Tootle R, et al. Resistance of three immortalized human hepatocyte cell lines to acetaminophen and N-acetyl-p-benzoquinoneimine toxicity. J Hepatol 1999;31:841-51.
37. McCloskey P, Tootle R, Selden C, et al. Modulation of hepatocyte function in an immortalized human hepatocyte cell line following exposure to liver-failure plasma. Artif Organs 2002;26:340-8.
38. Morsiani E, Pazzi P, Puviani AC, et al. Early experiences with a porcine hepatocyte-based bioartificial liver in acute hepatic failure patients. Int J Artif Organs 2002;25:192-202.
39. Stange J, Ramlow W, Mitzner S, et al. Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif Organs 1993;17:809-13.
40. Hughes R, Ton HY, Langley P, et al. Albumin-coated Amberlite XAD-7 resin for hemoperfusion in acute liver failure. Part II: in vivo evaluation. Artif Organs 1979;3:23-6.
41. Falkenhagen D, Strobl W, Vogt G, et al. Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances. Artif Organs 1999;23:81-6.
42. Rifai K, Ernst T, Kretschmer U, et al. Prometheus - a new extracorporeal system for the treatment of liver failure. J Hepatol 2003;39:984-90.
43. Matsumura KN, Guevara GR, Huston H, et al. Hybrid bioartificial liver in hepatic failure: preliminary clinical report. Surgery 1987;101:99-103.
44. Chen SC, Hewitt WR, Watanabe FD, et al. Clinical experience with a porcine hepatocyte-based liver support system. Int J Artif Organs 1996;19:664-9.
45. Samuel D, Ichai P, Feray C, et al. Neurological improvement during bioartificial liver sessions in patients with acute liver failure awaiting transplantation. Transplantation 2002;73:257-64.
46. Stevens AC, Busuttil R, Han S, et al. An interim analysis of a phase II/III prospective randomized, multicenter, controlled trial of the Hepatassist(R) bioartificial liver support system for the treatment of fulminant hepatic failure. Hepatology 2001;34:299A.
47. Ellis AJ, Hughes RD, Wendon JA, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996;24:1446-51.
48. Millis JM, Kramer DJ, O'Grady J, et al. Results of phase I trial of the extracorporeal liver assist device for patients with fulminant hepatic failure. Am J Transplantation 2001;1(suppl 1):391.
49. van de Kerkhove MP, Di Florio E, Scuderi V, et al. Phase I clinical trial with the AMC-bioartificial liver. Academic Medical Center. Int J Artif Organs 2002;25:950-9.
50. Sauer IM, Kardassis D, Zeillinger K, et al. Clinical extracorporeal hybrid liver support-phase I study with primary porcine liver cells. Xenotransplantation 2003;10:460-9.
51. Mitzner SR, Klammt S, Peszynski P, et al. Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system. Ther Apher 2001;5:417-22.
52. Sarkine P, Ben Abraham R, Szold O, et al. Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure. Crit Care Med 2001;29:1332-6.
53. Stange J, Mitzner SR, Risler T, et al. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 1999;23:319-30.
54. Mitzner SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000;6:277-86.
55. Heemann U, Treichel U, Loock J, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002;36:949-58.
56. Sen S, Rose C, Ytrebo LM, et al. Molecular adsorbents recirculating systems (MARS): A potential model for removing midazolam, fentanyl and possibly other protein-bound drugs. Hepatology 2003;38:238A.
57. Sen S, Davies NA, Mookerjee RP, et al. Pathophysiological basis of extracorporeal albumin dialysis with MARS in acute-on-chronic liver failure due to alcohol. Hepatology 2003;38:239A.
58. Sen S, Jalan R, Williams R. Liver failure: basis of benefit of therapy with the molecular adsorbents recirculating system. Int J Biochem Cell Biol 2003;35:1306-11.
59. Steiner C, Zinggrebe A, Viertler A. Experiences with MARS therapy in liver disease: analysis of 385 patients of the International MARS Registry. Hepatology 2003;38:239A.
60. Sen S, Steiner C, Williams R, et al. Artificial liver support: overview of registry and controlled clinical trials. In: Arroyo V, Forns X, Garcia-Pagan JC, et al, eds. Progress in the treatment of liver diseases. Barcelona: Ars Medica, 2003:429-35.
61. Kjaergard LL, Liu J, Als-Nielsen B, et al. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA 2003;289:217-22.
62. Stange J, Mitzner SR, Klammt S, et al. Liver support by extracorporeal blood purification: a clinical observation. Liver Transpl 2000;6:603-13.
63. Jalan R, Sen S, Steiner C, et al. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol 2003;38:24-31.